Factory Free sample Tetracaine - Olaparib AZD-2281 CAS 763113-22-0 Purity ≥99.0% API Factory – Ruifu

Short Description:

Product Detail

Product Tags

Feedback (2)

Gaining purchaser gratification is our firm's intention eternally. We will make wonderful endeavours to build new and top-quality merchandise, satisfy your exclusive needs and provide you with pre-sale, on-sale and after-sale products and services for CAS 83150-76-9, Tos-Phe-OH, Lapatinib Ditosylate CAS 388082-78-8, We glance forward to receiving your enquires shortly and hope to have the opportunity to function along with you inside the future. Welcome to acquire a glimpse at our organization.

Factory Free sample Tetracaine - Olaparib AZD-2281 CAS 763113-22-0 Purity ≥99.0% API Factory – Ruifu Detail:

Supply With High Purity, Commercial Production

Chemical Name	Olaparib
Synonyms	AZD-2281; KU0059436; Lynparza; 4-(3-(4-(cyclopropanecarbonyl)piperazine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one; 1-(Cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)Methyl]-2-fluorobenzoyl]piperazin
CAS Number	763113-22-0
CAT Number	RF-API103
Stock Status	In Stock, Production Scale Up to Hundreds of Kilograms
Molecular Formula	C24H23FN4O3
Molecular Weight	434.46
Solubility	Soluble in DMSO
Brand	Ruifu Chemical

Item	Specifications
Appearance	White to Off-White Powder
Identification by 1H NMR	Comply with the structure
LC-MS	Comply with the structure
Purity / Analysis Method	≥99.0% (by LC-MS)
Moisture (K.F)	≤0.50%
Single Impurity	≤0.50%
Total Impurities	≤1.0%
Heavy Metals (as Pb)	≤20ppm
Test Standard	Enterprise Standard
Usage	API; PARP Inhibitor

Package: Bottle, Aluminium foil bag, Cardboard Drum, 25kg/Drum, or according to customer’s requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.

Olaparib (CAS: 763113-22-0), a highly potent and selective PARP-inhibitor. In December 19, 2014, the FDA approved novel anti-cancer drug Olaparib (Lynparza) for monotherapy to the patients of advanced ovarian cancer who has undergone at least 3 rounds of chemotherapy or patients of suspected BRCA mutations. At the same time, FDA approved the quantitation and classification of diagnostic kits for the detection of mutations in BRCA1 and BRCA2, BRACAnalysis CDx. Olaparib is the first PARP inhibitor drugs which has been approved by FDA. In February 2, 2015, the European Union Food and Drug Administration (EMA) also approved Olaparib to enter into market in the 28 countries of European Union including Iceland, Liechtenstein and Norway. But the indications of EMA and FDA approved are slightly different; the former is for the BRCA gene mutation cases, and also for the maintenance therapy for patients of advanced epithelial ovarian cancer who has previously received platinum-containing chemotherapy drugs and exhibit response and subject to recurrence.

Product detail pictures:

Related Product Guide:

Fast and good quotations, informed advisers to help you choose the correct product that suits all your needs, a short production time, responsible quality control and different services for paying and shipping affairs for Factory Free sample Tetracaine - Olaparib AZD-2281 CAS 763113-22-0 Purity ≥99.0% API Factory – Ruifu , The product will supply to all over the world, such as: Kazakhstan, Norwegian, Palestine, All our products are exported to clients in the UK, Germany, France, Spain, the USA, Canada, Iran, Iraq, the Middle East and Africa. Our products are well welcomed by our customers for the high quality, competitive prices and the most favorable styles. We hope to establish business relationship with all customers and bring more beautifu colors for the life.